Olivier Hanon1, Jean-Sébastien Vidal2, Sylvain Lehmann3, Stéphanie Bombois4, Bernadette Allinquant5, Jean-Marc Tréluyer6, Patrick Gelé7, Christine Delmaire4, Fredéric Blanc8, Jean-François Mangin9, Luc Buée7, Jacques Touchon10, Jacques Hugon11, Bruno Vellas12, Evelyne Galbrun13, Athanase Benetos14, Gilles Berrut15, Elèna Paillaud16, David Wallon17, Giovanni Castelnovo18, Lisette Volpe-Gillot19, Marc Paccalin20, Philippe-Henri Robert21, Olivier Godefroy22, Thierry Dantoine23, Vincent Camus24, Joël Belmin25, Pierre Vandel26, Jean-Luc Novella27, Emmanuelle Duron2, Anne-Sophie Rigaud2, Suzanna Schraen-Maschke7, Audrey Gabelle10. 1. Memory Resource and Research Centre of de Paris-Broca-Ile de France, Hopital Broca, APHP, Paris, France; EA 4468, Université Paris Descartes, Sorbonne Paris Cité, Paris, France. Electronic address: olivier.hanon@aphp.fr. 2. Memory Resource and Research Centre of de Paris-Broca-Ile de France, Hopital Broca, APHP, Paris, France; EA 4468, Université Paris Descartes, Sorbonne Paris Cité, Paris, France. 3. Laboratoire de Protéomique Clinique, Department of Biochemistry, Saint Eloi Hospital, IRMB, Inserm U1183, Université de Montpellier, Montpellier, France. 4. Memory Clinic, CHU Lille, Lille, France; Université Lille, Inserm U1171, Degenerative and Vascular Cognitive Disorders, Lille, France. 5. Inserm UMR_S 894, Université Paris Descartes, Paris, France. 6. Unité de recherche Clinique, Hôpital Universitaire Necker-Enfants Malades, APHP, Université Paris Descartes, Paris, France. 7. Department of Biology and Pathology, CHU de Lille, Lille, France; Université Lille, INSERM UMRS 1172, Alzheimer's & Tauopathies, Centre de Biologie Pathologie Génétique, CHU Lille, Lille, France. 8. Memory Resource and Research Centre of Strasbourg/Colmar, CHRU de Strasbourg, Strasbourg, France; University of Strasbourg and French National Centre for Scientific Research (CNRS), ICube Laboratory and Fédération de Médecine Translationnelle de Strasbourg (FMTS), Team Imagerie Multimodale Intégrative en Santé (IMIS)/Neurocrypto, Strasbourg, France. 9. CATI Multicenter Neuroimaging Platform, Neurospin, CEA, cati-neuroimaging.com, Paris Saclay University, Gif-sur-Yvette, France. 10. Memory Resource and Research Centre of Montpellier, Department of Neurology, CHU Gui de Chauliac, Université de Montpellier, Montpellier, France. 11. Memory Resource and Research Centre of Paris Nord-Ile de France, Groupe Hospitalier Saint Louis-Lariboisière-Fernand Widal, APHP, Paris, France; University of Paris Diderot, Sorbonne Paris Cité, Paris, France. 12. Memory Resource and Research Centre of Midi-Pyrénées, CHU La Grave-Casselardit, Toulouse, France. 13. Department of Gérontology 2, Centre Hospitalier Émile-Roux, AP-HP, Limeil-Brévannes, France. 14. Memory Resource and Research Centre of Lorraine, CHU de Nancy, Nancy, France. 15. Memory Research Resource Center of Nantes, CHU de Nantes, Nantes, France. 16. Department of Internal Medicine and Geriatrics, Hôpital Henri-Mondor, APHP, Créteil, France. 17. Memory Resource and Research Centre of Haute-Normandie, CHU Charles Nicolle, Rouen, France; Inserm U1079, IRIB, Université de Rouen-Normandie, Rouen, France. 18. Neurology Department, CHU de Nimes, Nimes, France. 19. Memory Clinic, Hôpital Léopold Bellan, Paris, France. 20. Memory Resource and Research Centre of Poitiers, CHU de Poitiers, Poitiers, France. 21. Memory Research Resource Center of PACA Est, CHU de Nice, Nice, France. 22. Memory Resource and Research Centre of Amiens Picardie, CHU d'Amiens-Picardie, Amiens, France. 23. Memory Research Resource Center of Limoges, CHU de Limoges, Limoges, France. 24. Memory Resource and Research Centre of Tours, CHRU de Tours, Tours, France; Inserm U930 Imagerie et Cerveau, Université François-Rabelais de Tours, Tours, France. 25. Service de Gériatrie à orientation Cardiologique et Neurologique, Hôpitaux Universitaires Pitie-Salpêtrière-Charles Foix, APHP, Paris, France; DHU FAST, Sorbonne Universités, UPMC Université Paris 06, Paris, France. 26. Memory Resource and Research Centre of Besançon-Franche-Comté, CHU de Besançon, Besançon, France; EA 481 Neuroscience, IFR 133, University of Bourgogne Franche-Comté, Besançon, France. 27. Memory Resource and Research Centre of Champagne Ardenne, CHU de Reims, Reims, France; EA 3797, Université de Reims Champagne Ardenne, Reims, France.
Abstract
INTRODUCTION: Diagnostic relevance of plasma amyloid β (Aβ) for Alzheimer's disease (AD) process yields conflicting results. The objective of the study was to assess plasma levels of Aβ42 and Aβ40 in amnestic mild cognitive impairment (MCI), nonamnestic MCI, and AD patients and to investigate relationships between peripheral and central biomarkers. METHODS: One thousand forty participants (417 amnestic MCI, 122 nonamnestic MCI, and 501 AD) from the Biomarker of AmyLoïd pepTide and AlZheimer's diseAse Risk multicenter prospective study with cognition, plasma, cerebrospinal fluid (CSF), and magnetic resonance imaging assessments were included. RESULTS: Plasma Aβ1-42 and Aβ1-40 were lower in AD (36.9 [11.7] and 263 [80] pg/mL) than in amnestic MCI (38.2 [11.9] and 269 [68] pg/mL) than in nonamnestic MCI (39.7 [10.5] and 272 [52] pg/mL), respectively (P = .01 for overall difference between groups for Aβ1-42 and P = .04 for Aβ1-40). Globally, plasma Aβ1-42 correlated with age, Mini-Mental State Examination, and APOE ε4 allele. Plasma Aβ1-42 correlated with all CSF biomarkers in MCI but only with CSF Aβ42 in AD. DISCUSSION: Plasma Aβ was associated with cognitive status and CSF biomarkers, suggesting the interest of plasma amyloid biomarkers for diagnosis purpose.
INTRODUCTION: Diagnostic relevance of plasma amyloid β (Aβ) for Alzheimer's disease (AD) process yields conflicting results. The objective of the study was to assess plasma levels of Aβ42 and Aβ40 in amnestic mild cognitive impairment (MCI), nonamnestic MCI, and ADpatients and to investigate relationships between peripheral and central biomarkers. METHODS: One thousand forty participants (417 amnestic MCI, 122 nonamnestic MCI, and 501 AD) from the Biomarker of AmyLoïd pepTide and AlZheimer's diseAse Risk multicenter prospective study with cognition, plasma, cerebrospinal fluid (CSF), and magnetic resonance imaging assessments were included. RESULTS: Plasma Aβ1-42 and Aβ1-40 were lower in AD (36.9 [11.7] and 263 [80] pg/mL) than in amnestic MCI (38.2 [11.9] and 269 [68] pg/mL) than in nonamnestic MCI (39.7 [10.5] and 272 [52] pg/mL), respectively (P = .01 for overall difference between groups for Aβ1-42 and P = .04 for Aβ1-40). Globally, plasma Aβ1-42 correlated with age, Mini-Mental State Examination, and APOE ε4 allele. Plasma Aβ1-42 correlated with all CSF biomarkers in MCI but only with CSF Aβ42 in AD. DISCUSSION: Plasma Aβ was associated with cognitive status and CSF biomarkers, suggesting the interest of plasma amyloid biomarkers for diagnosis purpose.
Authors: Angharad R Morgan; Samuel Touchard; Claire Leckey; Caroline O'Hagan; Alejo J Nevado-Holgado; Frederik Barkhof; Lars Bertram; Olivier Blin; Isabelle Bos; Valerija Dobricic; Sebastiaan Engelborghs; Giovanni Frisoni; Lutz Frölich; Silvey Gabel; Peter Johannsen; Petronella Kettunen; Iwona Kłoszewska; Cristina Legido-Quigley; Alberto Lleó; Pablo Martinez-Lage; Patrizia Mecocci; Karen Meersmans; José Luis Molinuevo; Gwendoline Peyratout; Julius Popp; Jill Richardson; Isabel Sala; Philip Scheltens; Johannes Streffer; Hikka Soininen; Mikel Tainta-Cuezva; Charlotte Teunissen; Magda Tsolaki; Rik Vandenberghe; Pieter Jelle Visser; Stephanie Vos; Lars-Olof Wahlund; Anders Wallin; Sarah Westwood; Henrik Zetterberg; Simon Lovestone; B Paul Morgan Journal: Alzheimers Dement Date: 2019-04-30 Impact factor: 21.566
Authors: Shannon L Risacher; Noelia Fandos; Judith Romero; Ian Sherriff; Pedro Pesini; Andrew J Saykin; Liana G Apostolova Journal: Alzheimers Dement (Amst) Date: 2019-07-26